research Editorial Comment
PSA levels help determine prostate size and guide treatment choices for benign prostatic hyperplasia.
Search
for
Sort by
Research
630-660 / 1000+ resultsresearch Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research The endoscopic surgical monitoring system-guided impact factors exploring of blood loss and fluid absorption during plasmakinetic TURP: a prospective study in high-risk BPH patients
Larger prostate size, longer surgery, and smoking increase risks, while finasteride and experienced surgeons reduce them during prostate surgery.
research Glatze in jungen Jahren könnte Risikofaktor für BPH sein
Early balding may be a sign of future prostate problems.
research Intervention beim PCa: leichte Pluspunkte für radikale Prostatektomie
Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.
research Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases
New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
research Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS
Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
research Significance of the polyglutamine tract polymorphism in the androgen receptor
The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
research Recent Advances in the Chemistry and Pharmacological Activity of New Steroidal Antiandrogens and 5α-Reductase Inhibitors
New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
research PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY
Finasteride reduces PSA levels by around 40-50% in BPH patients.
research Structure of human type II 5 alpha-reductase gene.
The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.
research Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
Certain drugs that block specific enzymes can help treat prostate diseases.
research Therapeutic Androgen Receptor Ligands
Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
research Finasteride for prostatic disease: an updated and comprehensive review
Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
research New approach to 3-oxo-4-aza-5α-androst-1-ene-17β-(--butylcarboxamide)
A new method was developed to make finasteride for treating hair loss.
research Finasterida: Diez Años De Uso Clínico. Revisión Sistemática De La Literatura
Finasteride effectively reduces symptoms of enlarged prostate with minimal side effects.
research Highly efficient nucleophilic addition of alkyl Grignard reagents to 17-ketosteroids in the presence of cerium(III) chloride: Synthesis of 17α-propyl-17β-hydroxy-4-androsten-3-one, an androgen receptor antagonist
Adding cerium(III) chloride to Grignard reagents improves the making of compounds that could treat prostate issues and hair loss.
research PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice
5ARIs like finasteride can help prevent prostate cancer and treat BPH, but guidelines should be updated to reflect this.
research Dutasteride, a novel dual 5-A reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients
Dutasteride reduces DHT more effectively than finasteride.
research Economic Issues in the Treatment of BPH
Combination therapy for BPH is cost-effective, especially for men with larger prostates.
research Effects of In Utero Exposure to D-004, a Lipid Extract from Roystonea regia Fruits, in the Male Rat: A Comparison with Finasteride
D-004 may be a natural alternative to finasteride for treating enlarged prostate and male baldness.
research Homology Modeling of 5-alpha-Reductase 2 Using Available Experimental Data
Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.
research 5ARIs and PSA: Evidences
5ARIs lower PSA levels, but other tests are needed to avoid missing aggressive prostate cancer.
research GYNECOMASTIA AFTER FINASTERIDE THERAPY
Finasteride may cause breast enlargement, low testosterone a risk factor.
research Scientific Evaluation of A Unani Pharmacopoeia-Based Formulation on BPH in Animal Model
The Unani Pharmacopoeia-Based Formulation significantly improved symptoms of enlarged prostate in rats.
research The search for bioactive compounds in tropical plants to target hormone imbalance associated diseases
Piper cubeba and Aquilaria sinensis may help prevent or treat prostate issues by balancing hormones.
research Crystal Structure and Synthesis of 17α-Hexanoyloxy-16β-methylpregna-4,6-diene-3,20-dione
A new compound that could treat various androgen-related conditions was created and analyzed.
research 복분자 미숙과 추출물이 전립선암 세포주와 전립선비대 백서모델에 미치는 영향
Unripe Rubus occidentalis extracts may help treat benign prostatic hyperplasia.
research Crystal Structure and Synthesis of 17.ALPHA.-Acetoxy-6,7-epoxypregn-4-ene-3,20-dione
A new compound was made that might help treat diseases related to male hormones.
research Editorial comment
Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.